Peterson Wealth Services Buys 435 Shares of Novo Nordisk A/S (NYSE:NVO)

Peterson Wealth Services raised its stake in shares of Novo Nordisk A/S (NYSE:NVOFree Report) by 1.1% in the fourth quarter, Holdings Channel reports. The fund owned 40,604 shares of the company’s stock after acquiring an additional 435 shares during the period. Novo Nordisk A/S comprises approximately 1.8% of Peterson Wealth Services’ holdings, making the stock its 16th biggest position. Peterson Wealth Services’ holdings in Novo Nordisk A/S were worth $4,201,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Key Financial Inc lifted its position in Novo Nordisk A/S by 8.5% during the 4th quarter. Key Financial Inc now owns 4,330 shares of the company’s stock worth $448,000 after buying an additional 340 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in Novo Nordisk A/S by 18.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 8,446 shares of the company’s stock worth $874,000 after buying an additional 1,300 shares in the last quarter. Rakuten Securities Inc. acquired a new position in Novo Nordisk A/S during the 4th quarter worth about $164,000. TRUE Private Wealth Advisors lifted its position in Novo Nordisk A/S by 82.4% during the 4th quarter. TRUE Private Wealth Advisors now owns 5,569 shares of the company’s stock worth $576,000 after buying an additional 2,516 shares in the last quarter. Finally, Wealth Alliance lifted its position in Novo Nordisk A/S by 2.7% during the 4th quarter. Wealth Alliance now owns 11,836 shares of the company’s stock worth $1,224,000 after buying an additional 313 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on NVO. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target on the stock. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Get Our Latest Analysis on Novo Nordisk A/S

Novo Nordisk A/S Trading Down 0.4 %

Novo Nordisk A/S stock traded down $0.49 during trading hours on Thursday, reaching $124.04. 667,553 shares of the company’s stock traded hands, compared to its average volume of 4,850,171. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The firm has a market capitalization of $556.63 billion, a price-to-earnings ratio of 45.69, a PEG ratio of 2.06 and a beta of 0.41. The firm’s 50 day moving average is $126.28 and its 200-day moving average is $110.42.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. On average, analysts predict that Novo Nordisk A/S will post 3.33 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were given a $0.664 dividend. This represents a dividend yield of 0.9%. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 49.17%.

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

See Also

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.